Nu Holdings’ NU accelerating customer count is the foundation of its continued success in Latin America. In the fourth quarter of 2025, the company reached 131 million customers across its

Amid macroeconomic uncertainty and volatile technology spending in 2026, the quantum computing industry is gradually transitioning from research-led experimentation toward early commercialization

Improved pricing, rising climate-related risks and rapid digitization are poised to shape the insurance industry's trajectory in 2026. While insurers continue to face exposure to catastrophe losses

Astronics Corporation’s ATRO Test Systems segment is gradually emerging as an important contributor to the company’s long-term growth, positioning it to benefit from structural expansion in

UiPath PATH ended its fiscal year on a strong note, reporting results that exceeded the upper end of its guidance across major financial metrics. The quarter reflected continued demand for

ImmunityBio IBRX is scaling a strategy that sits at the intersection of a persistent Bacillus Calmette-Guérin (BCG) shortage and expanding use of its lead immunotherapy, Anktiva. That combination is

• (1:00) - Where Can You Find Strong Investments For A Deal?
• (5:45) - Tracey’s Top Stock Picks For Your Watchlist Right Now
• (23:00) - Episode Roundup: CLDT, INNV, BCBP
•                 Podcast@Zacks.

ImmunityBio’s IBRX stock has re-rated sharply as Anktiva transitions from a newly launched therapy to a product with accelerating prescriptions, expanding geographies, and active label-extension

ImmunityBio IBRX has entered a new phase as a commercial-stage immunotherapy developer. The company’s near-term trajectory is closely tied to a single asset, Anktiva, which now anchors both revenue